Authors analyze actual situation in treatment of cardiovascular diseases in older patients. Different groups of recommended drugs are discussed separately; possible risks for elderly patients are stressed. Angiotensin converting enzyme inhibitors-this group is widely used in older patients because of their hypotensive effect, positive influence on cardiac failure, and positive modulation of endothelial dysfunction. The risk of hyperkalemia must be considered. Antiaggregants and anticoagulants are proved as potent prophylactic treatment, but the associated risk of gastrointestinal bleeding must be weighed very carefully. Bradycardia related to β-blockers, especially in combination with other medications lowering the heart rate must be taken into account. Otherwise, this group brings the highest profit in cardiovascular diseases as for morbidity and mortality. Attention is paid to calcium channel blockers, statins, diuretics, nitrates, and digoxin. A table listing the possible side effects and clinical symptoms of overdose by medications most frequently used in the elderly concludes the article.

Department of Internal Medicine Geriatrics and Practical Medicine Masaryk University Faculty of Medicine and Brno Faculty Hospital Czech Republic

Zobrazit více v PubMed

Neurology. 2008 Jun 10;70(24):2291-8 PubMed

Heart. 2013 Apr;99(8):520-7 PubMed

Wien Klin Wochenschr. 2012 May;124(9-10):340-7 PubMed

Wien Klin Wochenschr. 2010 Aug;122(15-16):511-4 PubMed

JAMA. 2005 Mar 16;293(11):1348-58 PubMed

Vnitr Lek. 2010 Feb;56(2):157-61 PubMed

Circulation. 2008 Apr 29;117(17):2262-9 PubMed

Mayo Clin Proc. 2008 May;83(5):595-9 PubMed

Arch Intern Med. 1997 Jul 28;157(14):1531-6 PubMed

Acta Med Austriaca. 2001;28(2):52-5 PubMed

Vnitr Lek. 2009 Oct;55(10):976-80 PubMed

CMAJ. 2008 Jun 3;178(12):1563-9 PubMed

Medicina (Kaunas). 2008;44(5):407-13 PubMed

ISRN Cardiol. 2012;2012:692761 PubMed

Clin Res Cardiol. 2008 Jul;97(7):418-31 PubMed

Arch Intern Med. 1991 Sep;151(9):1825-32 PubMed

Vnitr Lek. 2010 Sep;56(9 Suppl):972-6 PubMed

Cardiovasc Interv Ther. 2013 Jan;28(1):22-9 PubMed

Int J Equity Health. 2008 Jun 30;7:16 PubMed

Eur J Heart Fail. 2009 Aug;11(8):802-5 PubMed

Vnitr Lek. 2009 Nov;55(11):1085-8 PubMed

J Thromb Haemost. 2008 Sep;6(9):1500-6 PubMed

Hypertens Res. 2008 Mar;31(3):455-62 PubMed

Vasc Health Risk Manag. 2008;4(2):363-81 PubMed

Clin Rheumatol. 2008 Sep;27(9):1191-4 PubMed

J Otolaryngol Head Neck Surg. 2008 Feb;37(1):11-5 PubMed

J Am Geriatr Soc. 2008 Jun;56(6):1021-7 PubMed

Cardiology. 2012;122(4):230-6 PubMed

CMAJ. 2008 May 6;178(10):1303-11 PubMed

Eur Heart J. 2013 Nov;34(41):3206-16 PubMed

Wien Klin Wochenschr. 2012 Mar;124(5-6):160-9 PubMed

Pol Arch Med Wewn. 2006 Mar;115(3):238-42 PubMed

Pharmacoepidemiol Drug Saf. 2008 Jun;17(6):587-92 PubMed

Expert Opin Drug Saf. 2012 Nov;11(6):1023-45 PubMed

Neurology. 2008 Jun 3;70(23):2219-25 PubMed

Hiroshima J Med Sci. 2008 Mar;57(1):17-25 PubMed

Clin Hemorheol Microcirc. 2008;39(1-4):385-9 PubMed

Am J Hypertens. 2008 Jun;21(6):674-8 PubMed

Curr Med Res Opin. 2008 Jul;24(7):1987-2000 PubMed

Eur Heart J. 2010 Oct;31(19):2369-429 PubMed

Can J Cardiol. 2008 Jun;24(6):507-12 PubMed

Circulation. 2008 Jul 29;118(5):576-85 PubMed

Wien Klin Wochenschr. 2011 Jan;123(1-2):21-7 PubMed

Presse Med. 2008 Jun;37(6 Pt 2):1047-54 PubMed

Clin Exp Hypertens. 2008 Apr;30(3):267-76 PubMed

Patient Relat Outcome Meas. 2011 Jul;2:27-39 PubMed

Cas Lek Cesk. 2006;145(9):708-11 PubMed

Wien Klin Wochenschr. 2011 Oct;123(19-20):611-7 PubMed

Eur J Heart Fail. 2009 Dec;11(12):1214-9 PubMed

Pharmacol Res. 2010 Jan;61(1):34-9 PubMed

Psychiatr Danub. 2008 Jun;20(2):162-7 PubMed

Int J Cardiol. 2009 Jun 12;135(1):128-30 PubMed